GLP‑1 Therapies in Addiction and Psychiatric Comorbidity

A narrative review in GLP‑1 receptor agonists surveys how this drug class has been studied in alcohol and other substance use disorders (ASUDs), alongside psychiatric and metabolic considerations. The abstract describes three evidence streams: preclinical experiments, observational cohort analyses using electronic health records, and a still-developing randomized clinical trial (RCT) literature. Across these streams, the authors conclude that randomized evidence is emerging and is critically needed to determine safety and efficacy in people with ASUDs.

On the experimental side, the study reports preclinical evidence across several models and species that has been consistent in direction, with GLP‑1 receptor agonists associated with reductions in drug intake and other addictive behaviors. Substances studied are described as primarily alcohol, with additional work noted in nicotine, opioids, and psychostimulants

In observational research, the study states that cohort studies drawing on electronic health records suggest improvements in ASUD-related outcomes among people receiving GLP‑1 receptor agonists for other indications. The authors characterize RCT evidence as limited to date and mixed in its results, while still described as overall promising, and they note that several RCTs are ongoing or about to start.

Regarding psychiatric safety, the study notes that some early pharmacovigilance alarms have been raised, but it also reports that GLP‑1 receptor agonists do not seem to cause or increase the risk of psychopathology, with examples including depression and suicidal ideation and/or behavior. The study also notes that some recent studies suggest beneficial effects on mental health outcomes, while emphasizing that more work is needed.

In its forward-looking discussion, the study ties the rationale for studying GLP‑1 therapies in ASUDs to overlap between feeding and metabolic pathways and those mediating addictive behaviors, and it highlights intersections with mental health and medical comorbidities as areas needing further study.

Key takeaways:

• The abstract reports consistent preclinical findings across models and species linking GLP‑1 receptor agonists with reduced drug intake and other addictive behaviors, with most work focused on alcohol and some on nicotine, opioids, and psychostimulants.
• The abstract describes observational electronic health record cohort signals for improved ASUD-related outcomes and portrays RCT evidence as limited and mixed but overall promising, with additional trials underway or about to start.
• The abstract notes early pharmacovigilance alarms but states GLP‑1 receptor agonists do not seem to increase risk of psychopathology, while also listing major evidence gaps spanning psychiatric/metabolic comorbidity, treatment parameters, and other unresolved research questions.